COPD

COPD Outpatient • GOLD 2026

Initial + follow-up maintenance therapy. FEV₁ grades prognosis; symptoms + exacerbations drive treatment.

GOLD A/B/E

Maintenance-treatment naïve

Initial
Moderate/severe exacerbations in last year
2026: even 1 moderate exacerbation = Group E
Symptom burden
Pick mMRC or CAAT. The calculator determines lower vs higher symptoms for GOLD A/B.
Calculate symptoms Choose a score
Choose the best fit:
GOLD split: mMRC 0-1 = lower symptoms · mMRC ≥2 = higher symptoms
Blood eosinophils
Mainly predicts ICS benefit for exacerbation prevention
cells/µL
Concomitant asthma?
If yes, asthma treatment drives ICS use

Diagnosis

  • Dyspnea, cough/sputum, recurrent “bronchitis,” exposure history
  • Confirm: post-BD FEV₁/FVC <0.70 in the right clinical context
  • Pre-BD FEV₁/FVC ≥0.70: usually excludes COPD; get post-BD if strong suspicion / volume response suspected
  • Post-BD ratio 0.60-0.80: repeat spirometry if diagnosis uncertain
  • Reversibility: does not reliably separate asthma from COPD and does not choose chronic COPD therapy
GOLD 1FEV₁ ≥80%
GOLD 2FEV₁ 50-79%
GOLD 3FEV₁ 30-49%
GOLD 4FEV₁ <30%
Do not use FEV₁ grade to pick A/B/E inhalers. Use it for airflow-obstruction severity/prognosis.

Outpatient Follow-Up

  • Every visit: symptoms, exacerbations, inhaler technique/adherence, tobacco + comorbidities
  • Smoking cessation: counseling + pharmacotherapy
  • Pulmonary rehab: Groups B/E; especially after hospitalization
  • Prevention: vaccines, physical activity, annual spirometry
  • One-time / eligibility checks: alpha-1 antitrypsin testing + lung cancer screening when indicated

Long-term Oxygen

  • PaO₂ ≤55 mmHg or SaO₂ ≤88% while stable
  • PaO₂ 55-60 or SaO₂ 88% + PH/cor pulmonale/peripheral edema or Hct >55%
Moderate resting/exertional desaturation alone has not shown the same survival benefit.

Acute Exacerbation

  • AECOPD: worsening dyspnea and/or cough/sputum over days, up to 14 days
  • Do not anchor: pneumonia, PE, acute HF, pneumothorax, arrhythmia/ACS can mimic or coexist

AECOPD

Disposition + steroids + antibiotics + respiratory support

Respiratory failure / gas
Choose the highest-acuity finding
New/increased O₂ requirement?
Marked WOB, AMS or hemodynamic instability?
Purulent sputum?
Antibiotic trigger
Prior positive bacterial sputum culture / recurrent lung infection?
Antibiotic + culture branch
Requires NIV or invasive ventilation?
Antibiotic trigger + inpatient care

AECOPD Quick Orders

Bronchodilators

  • Albuterol 2.5 mg neb or MDI equivalent; repeat to response
  • Ipratropium 0.5 mg neb q6-8h in moderate/severe AECOPD
  • Resume/initiate maintenance LABD early once stable

Steroid

  • Prednisone 40 mg PO daily × 5 days
  • PO preferred when feasible
  • No routine methylpred 125 mg IV loading dose

Antibiotics

  • 5 days if purulent sputum, prior positive bacterial sputum culture/recurrent lung infection, or NIV/IMV
  • Use prior cultures/local antibiogram when resistant GNR/Pseudomonas risk

Gas Exchange

  • SpO₂ 88-92%
  • Acute hypoxemic RF: HFNT first
  • Hypercarbic RF/acidosis or HFNT failure: NIV

AECOPD Antibiotics

Route + empiric regimen when antibiotics are indicated

Prefer PO when feasible. Use oral therapy when the patient can absorb/tolerate medication and does not otherwise require IV therapy.
Pseudomonas risk
Antibiotic Oral dose
Standard oral options
Azithromycin 500 mg day 1, then 250 mg daily ×4 days
or 500 mg daily ×3 days
Clarithromycin 500 mg IR BID
or 1 g ER daily
Amoxicillin-clavulanate 875/125 mg BID
or 500/125 mg TID
Cefuroxime 2nd-generation cephalosporin 500 mg BID
Cefdinir 3rd-generation cephalosporin 300 mg BID or 600 mg daily
Cefpodoxime 3rd-generation cephalosporin 200 mg BID
Fluoroquinolones
Levofloxacin Anti-Pseudomonas at 750 mg No Pseudomonas risk: 500 mg daily
Pseudomonas risk: 750 mg daily
Moxifloxacin 400 mg daily
Ciprofloxacin Anti-Pseudomonas 750 mg BID
Duration: generally 5 days if improving; GOLD recommends ≤5 days for outpatient AECOPD. Tailor to cultures, renal function, allergy history + local antibiogram.

Poor Response? Reconsider Diagnosis

  • Pneumonia / aspiration
  • Acute HF / pulmonary edema
  • PE / pneumothorax
  • ACS / arrhythmia
  • Mucus plugging / atelectasis
  • Wrong inhaler delivery, missed meds, ongoing exposure

Discharge

  • Maintenance LABD: start/resume before or immediately after discharge
  • After ≥1 moderate/severe exacerbation: check eos; add ICS to LABA/LAMA when phenotype supports benefit
  • Technique + adherence: watch inhaler use
  • Smoking cessation + vaccines + pulmonary rehab
  • Action plan + early follow-up: symptoms, O₂ need, med access + prevention plan
References
1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report. 2026.
View GOLD 2026 report
Primary Guideline
2
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pocket Guide to COPD Diagnosis, Management, and Prevention: 2026. 2026.
View GOLD Pocket Guide
Quick Reference
3
Agustí A, Vila M, Sisó-Almirall A, et al. Key recommendations for primary care from the 2026 GOLD update. npj Prim Care Respir Med. 2026. doi:10.1038/s41533-026-00544-z.
View publication
2026 GOLD Update
4
Agustí A, Halpin DMG, Celli B, Vogelmeier CF. Clarifying the GOLD 2026 guidance for initial pharmacological COPD treatment. Eur Respir J. 2026;68(1):2600549. doi:10.1183/13993003.00549-2026.
View publication
Initial Inhaler Therapy
5
Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/13993003.00791-2016.
View ERS/ATS guideline
COPD Exacerbations
Guideline-based clinical reference. Antibiotic selection should account for prior cultures, allergy history, renal function, and local resistance patterns.